Skip to content

Covid-19 coronavirus: key regulatory and enforcement risks

Headlines in this article

Related news and insights

Blog Post: 20 June 2022

Breaking: Global Covid-19 IPR waiver approved

Blog Post: 05 January 2022

COVID-19 – the distinction between vaccines and vaccination

Publications: 03 December 2021

Hybrid ways of working: a new normal

Blog Post: 12 October 2021

Global Covid-19 IPR waiver negotiations

The Covid-19 coronavirus pandemic has brought unprecedented global challenges across all industries.  Each day brings new medical information, a new projection on the economic impact, and seemingly never-ending uncertainty about the future.  

As companies grapple with this new reality and position themselves to survive the crisis, and then thrive once the crisis ends, Allen & Overy has been actively monitoring the risks companies face from a regulatory and enforcement perspective.  While companies must rightly focus on their pressing short-term needs and commercial issues, a key lesson from the 2008 financial crisis should not be forgotten: the economic turmoil sparked a years-long wave of regulatory and enforcement action targeting crisis-era conduct. 

With that lesson in mind, this note contains guidance across a range of regulatory and enforcement risks that companies across different industries are grappling with during the Covid-19 crisis, including securities, commodities and related derivatives, antitrust, anti-corruption, anti-money laundering, sanctions, foreign investment, and political law.

We identify key risks and suggest mitigation strategies.  More in-depth analyses on specific issues and industries can be found below, and will be updated.


Securities

Antitrust

 

Recommended content